We thought Actavis had a love triangle going with potential merger partners Warner Chilcott and Valeant Pharmaceuticals, as an analyst dubbed it earlier this week. Now, news emerges that it's more like a love quadrangle, with rejections on two sides.
While Valeant Pharmaceuticals was chatting up Actavis about a potential merger-of-equals, Actavis was apparently mulling a bid for Warner Chilcott, the Irish drugmaker that specializes in women's health and dermatology.
A union fund is suing Warner Chilcott, Watson Laboratories and Lupin, claiming that their Loestrin 24 Fe patent settlements amounted to unfair market-sharing deals that cost payers money. Warner's key patent on the formula was weak, the fund claims, and the generics makers only backed away because Warner paid them to.
Two former Warner Chilcott reps have blown the whistle. In a False Claims Act lawsuit unsealed last week, the ex-salespeople detail a long series of allegations, including kickbacks, privacy violations and off-label shenanigans.
Endo Health Solutions' is feeling the generics pain this year as its key products face copycats and that may be enough to have sent it looking for a buyer.
Harris Interactive has been digging into physicians' response to drug brands, therapeutic area by therapeutic area, racking up more evidence for an emotional variable in the doctor-drug trust equation.
The Federal Trade Commission 's campaign for generic drugs has taken a new twist. The agency, long an opponent of "pay for delay" patent settlements, is now taking up the banner against product tweaks that can keep brands protected for years after initial patents expire.
A few months ago, Warner Chilcott put itself up for sale. Last month, it said "No deal." Now, its top shareholders are conducting a sale of their own, aiming to cash out more than half of their stakes in the company. And after that news broke, other shareholders started unloading, too.
No one made an offer Warner Chilcott ($WCRX) couldn't refuse. So the Irish drugmaker says it's not selling itself after all. Instead, it will spend $1 billion on a $4-per-share dividend, presumably as a consolation prize for shareholders.
Japanese drugmaker Astellas Pharma got what it was hoping for and what it badly needs, FDA approval of its new bladder treatment, mirabegron, branded Myrbetriq.